PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1193440
PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1193440
Gammaretroviral Vector Market size was valued at USD 680.6 Million in 2022, expanding at a CAGR of 17.9% from 2023 to 2030.
In laboratory investigations, gamma retroviruses serve as retroviral vectors. For gene therapy and gene transfer, these vectors are indispensable. They are so beneficial because their genomes are user-friendly and basic. Animals are subject to a variety of ramifications from gamma retroviruses. They have been connected to a number of illnesses, including as cancer, notably leukemias and lymphomas, neurological conditions, and immunodeficiencies in many species.
The growing prevalence of cancer and genetic illnesses is increasing, which is accelerating gammaretroviral vector market growth. Lung cancer, breast cancer, and colorectal cancer are the three cancers that cause the most deaths worldwide, according to the World Health Organization. The most common cancers include breast cancer, lung cancer, prostate cancer, colon cancer, and rectum cancer. One of the main drivers of the global gammaretroviral vector market is the increasing prevalence of cancer, genetic diseases, and infectious diseases, which is increasing the demand for vector-based gene therapies, cell therapies, and vaccines.
The quick use of viral and plasmid vectors for the creation of novel therapeutics is another factor driving market growth. Furthermore, compared to depending on transient transfection techniques, the creation of stable producer cell lines during upstream processing can offer a number of benefits. In addition to cost savings on clinical-grade plasmids and transfection agents, stable cell lines usually yield viral particles of greater quality. They will offer cleaner harvests and less potential batch-to-batch variability because they are almost homologous. In addition to being more scalable than transient transfection techniques, stable producer cell lines can be employed for small- or large-scale production, depending on the quantities necessary.
The Global Gammaretroviral Vector Market is segmented on the basis of Type, Application, End User, and Region.
The market is split into four categories based on Type: lentiviral vectors, adenoviral vectors, adeno-associated viral vectors, and others. The lentiviral vectors segment dominates the market. Growing demand for cancer treatments is mainly contributing to segment growth.
The market is segmented into two categories based on application: gene therapy and vaccinology. The gene therapy segment dominates the market and is likely to maintain its dominance during the forecast period. This is partly due to a rise in the demand for therapy-based diagnostics.
The market is segmented into four categories based on end user: research organizations, pharma & biotech, and others. The pharma & biotech segment dominates the market and is likely to maintain its dominance during the forecast period. This is partly due to an increase in the demand for gammaretroviral vector in pharma and biotech developments is boosting the segment growth.
The worldwide market for gammaretroviral vector is moderately fragmented in nature which comprised of large and small-sized market players with few large dominating the global market share. Companies in the industry place a strong emphasis on implementing aggressive strategies to reach a broad customer base. Some of the primary techniques used by corporations to strengthen their reach and expand their market share include new product launches, partnerships, distribution network development, R&D spending, and mergers and acquisitions.
For instance, in 2022, Thermo Fisher Scientific Inc., acquires viral vector manufacturing business from Novasep.
Key features of the study:
This proposed research study on Gammaretroviral Vector market provides market size (US$ million), compound annual growth rate (CAGR %) and forecast estimation (2023-2030), considering 2022 as the base year
The research report elucidates potential growth opportunities across different segments/countries and explains attractive investment proposition matrix for Gammaretroviral Vector market
The overall report identifies new investment opportunities, challenges faced by established players, and growth factors to sustain in the Gammaretroviral Vector market
Impact of COVID-19 on Gammaretroviral Vector market size, forecast, CAGR, and market dynamics are discussed in detail under the research scope. Detailed insight on Gammaretroviral Vector market post-COVID will also be covered.
In order to give the users of this report a comprehensive view on the Gammaretroviral Vector market, we have also included competitive landscape and key innovator analysis for the Gammaretroviral Vector market.
The study encompasses a growth prospect mapping analysis, wherein all the industry segments are benchmarked based on their market size, growth rate and attractiveness.
The report offers detailed company profiling featuring major market participants which will help users to understand their financial information and strategic initiatives of players operating in the Gammaretroviral Vector market.
In addition, the report also unveil the important acquisitions & mergers, collaborations & joint ventures, new launch, research & development, regional expansion of major participants involved in the market on global as well as regional level.
The global Gammaretroviral Vector market report primarily caters to various stakeholders in this industry including suppliers, investors, new entrants, distributors, and financial analysts
SCOPE OF THE REPORT
The scope of this report covers the market by its major segments, which include as follows:
GLOBAL GAMMARETROVIRAL VECTOR MARKET KEY PLAYERS
Charles River Laboratories
Thermo Fisher Scientific Inc
Spark Therapeutics Inc.
Boehringer Ingelheim International GmbH
GLOBAL GAMMARETROVIRAL VECTOR MARKET, BY TYPE
Adeno-Associated Viral Vectors
GLOBAL GAMMARETROVIRAL VECTOR MARKET, BY APPLICATION
GLOBAL GAMMARETROVIRAL VECTOR MARKET, BY END USER
Pharma & biotech
GLOBAL GAMMARETROVIRAL VECTOR MARKET, BY REGION
Rest of Europe
Rest of APAC
Rest of LATAM
The Middle East and Africa
United Arab Emirates
Rest of MEA